Finch Therapeutics Group Long Term Debt

Finch Therapeutics Group (FNCH) currently reports a long-term debt of $27M as of June 2024. That compares with $29M in the prior-year period — down 8.5% year over year. Use the charts on this page to explore Finch Therapeutics Group's long-term debt history and peer comparisons.

Finch Therapeutics Group's long-term debt decreased from $29M to $27M — a 8.5% year-over-year decrease (period ending June 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Finch Therapeutics Group reported $27M in long-term debt as of June 2024. That compares with $29M in the prior-year period — down 8.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $27M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Finch Therapeutics Group, and consider following FNCH for alerts when major investors trade the stock.

Finch Therapeutics Group is classified in the Healthcare sector. On long-term debt, it currently shows $27M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing FNCH with unrelated industries.